Renal cell carcinoma remains a biomarker-challenged disease in which PD-L1 and tumor mutational burden have limited predictive value, while PBRM1 status, VHL-driven pseudohypoxia, and spatial immune architecture are biologically informative but not yet clinically validated as stand-alone selection tools. This evidence concerns the gene PBRM1 and renal cell carcinoma.